Diabetes Metab J.  2011 Jun;35(3):282-289. 10.4093/dmj.2011.35.3.282.

Factors Associated with Long-Term Oral Hypoglycemic Agent Responsiveness in Korean Patients with Type 2 Diabetes Mellitus

• Kim BY
• Jung CH
• Mok JO
• Kim CH

• KMID: 2175438
• DOI: http://doi.org/10.4093/dmj.2011.35.3.282

Abstract

BACKGROUND
This study was performed to determine the factors associated with long-term oral hypoglycemic agent (OHA) responsiveness in Korean type 2 diabetic patients.
METHODS
Two groups of patients were selected among the type 2 diabetic patients who were followed for more than two years at a university hospital diabetes clinic. The OHA responsive group consisted of 197 patients whose HbA1c levels were maintained at < or =7% with OHA for more than two years. The OHA failure group consisted of 180 patients whose HbA1c levels were >8% in spite of optimal combined OHA therapy or patients who required insulin therapy within the two years of the study.
RESULTS
The OHA failure group had higher baseline values of fasting and postprandial glucose, HbA1c, and lower fasting, postprandial, and delta C-peptide compared to those of the OHA responsive group. The OHA failure group also had a higher proportion of female patients, longer diabetic duration, and more family history of diabetes. There were no significant differences in body mass index (BMI) or insulin resistance index between the two groups. Multiple logistic regression analysis showed that the highest quartile of baseline fasting, postprandial glucose, and HbA1c and the lowest quartile of postprandial and delta C-peptide were associated with an increased odds ratio of OHA failure after adjustment for age, sex, body mass index, and family history of diabetes.
CONCLUSION
Lower baseline values of postprandial and delta C-peptide and elevated fasting glucose and HbA1c are associated with long-term OHA responsiveness in Korean patients with type 2 diabetes mellitus.

Keyword

C-peptide; Diabetes mellitus, type 2; Oral hypoglycemic agent responsiveness

MeSH Terms

Body Mass Index
C-Peptide
Diabetes Mellitus, Type 2
Fasting
Female
Glucose
Humans
Insulin
Insulin Resistance
Logistic Models
Odds Ratio
C-Peptide
Glucose
Insulin

Figure

• 

  Fig. 1 Receiver operating characteristic curves for the prediction of oral hypoglycemic agent failure in Korean type 2 diabetic patients. (A) HbA1c, fasting and postprandial plasma glucose. (B) Fasting, postprandial, and delta C-peptides.

Reference

1. Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008. 9:193–205.

2. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995. 310:83–88.

3. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002. 48:436–472.

4. Peacock I, Tattersall RB. The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin? Br Med J (Clin Res Ed). 1984. 288:1956–1959.

5. Koskinen P, Viikari J, Irjala K, Kaihola HL, Seppala P. C-peptide determination in the choice of treatment in diabetes mellitus. Scand J Clin Lab Invest. 1985. 45:589–597.

6. Kyllastinen M, Elfving S. Serum C-peptide concentrations and their value in evaluating the usefulness of insulin therapy in elderly diabetics. Gerontology. 1986. 32:317–326.

7. Nielsen NV, Tronier B. C-peptide in diabetes mellitus treated with insulin. A 3-year epidemiological study on the island of Falster, Denmark. Diabetes Res. 1986. 3:475–478.

8. Keller U, Pasquel M, Berger W. C-peptide determination in diabetics for the evaluation of insulin requirements. Schweiz Med Wochenschr. 1987. 117:187–192.

9. Asano T, Kawamura M, Watanabe T, Abe M, Chin R, Miyazaki S, Hirata Y. Indices of urinary and serum C-peptide corrected with fasting plasma glucose for decision-making of insulin therapy in type 2 diabetes-validation and comparison. J Jpn Diabetes Soc. 2008. 51:759–763.

10. Ko GT, So WY, Tong PC, Chan WB, Yang X, Ma RC, Kong AP, Ozaki R, Yeung CY, Chow CC, Chan JC. Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus. CMAJ. 2009. 180:919–926.

11. Goto A, Takaichi M, Kishimoto M, Takahashi Y, Kajio H, Shimbo T, Noda M. Body mass index, fasting plasma glucose levels, and C-peptide levels as predictors of the future insulin use in Japanese type 2 diabetic patients. Endocr J. 2010. 57:237–244.

12. Shim WS, Kim SK, Kim HJ, Park SE, Kang ES, Rhee YM, Ahn CW, Lim SK, Kim KR, Lee HC, Cha BS. Clinical meaning of postprandial insulin secretory function in Korean type 2 diabetes mellitus. J Korean Diabetes Assoc. 2005. 29:367–377.

13. Kim RS, Yang IM, Kim JW, Kim YS, Kim KW, Kim SW, Choi YK. Postprandial 2-hr C-peptide concentration as a guide for insulin treatment in patient with NIDDM. Korean J Intern Med. 1986. 1:120–125.

14. Yoo HJ, Kim DM, Sung SK, Wee SO. Serum C-peptide concentration as an index of insulin treatment in NIDDM patients. J Korean Diabetes Assoc. 1987. 11:57–61.

15. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia. 1985. 28:119–121.

16. Madsbad S, Krarup T, McNair P, Christiansen C, Faber OK, Transbol I, Binder C. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand. 1981. 210:153–156.

17. Kim YK, Jeon JS, Lee JH, Ahn MA, Shong MH, Ro HK, Song CU, Yoon SI, Ku BJ. Practical clinical value of C-peptide test in the choice of insulin treatment in patients with noninsulin dependent diabetes mellitus. J Korean Diabetes Assoc. 1995. 19:196–201.

18. Hue SH, Shin SH, Kim YS, Seo YK, Seol MJ, Oh YS. Practical value of glucagon test in the choice of treatment in diabetic patients. J Korean Diabetes Assoc. 1985. 11:63–69.

19. Park YS, Kim WB, Hong SK, Kim YS, Lee MK, Kim SY, Cho BY, Lee HK, Koh CS, Min HK, Rhee BD. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide in relation to clinical type of diabetes. J Korean Med Assoc. 1991. 34:655–665.

20. Pasquali R, Buratti P, Biso P, Patrono D, Capelli M, Pasqui F, Melchionda N. Estimation of B-cell function by the urinary excretion rate of C-peptide in diabetic patients: comparison with C-peptide response to glucagon and to a mixed meal. Diabete Metab. 1987. 13:44–51.